The earnings call highlighted significant progress in reducing operating and R&D expenses, extending the cash runway, and preparing for the potential market launch of ORLYNVAH. However, challenges include increased G&A expenses, the inability to secure a strategic partner, competition from new market entrants, and ongoing net losses. While there are positive steps toward commercialization, the balance of highlights and lowlights suggests a cautious outlook.

Company Guidance -

Q2 2025

During the Iterum Therapeutics plc first quarter 2025 earnings call, the company provided guidance on several key metrics. The potential commercialization of ORLYNVAH is planned for the fourth quarter of 2025, targeting the U.S. market for uncomplicated urinary tract infections. With approximately 40 million prescriptions generated annually in the U.S., ORLYNVAH's addressable market is estimated at around 26 million prescriptions for at-risk patients. Iterum anticipates capturing a 1% market share could result in over $250 million in annual net sales. Financially, Iterum reported a reduction in operating expenses to $3.7 million for Q1 2025 from $6.2 million in the same period in 2024, with a net loss of $4.9 million on a GAAP basis. The company ended March 2025 with $12.7 million in cash and cash equivalents, with a cash runway extended into 2026, alongside recent fundraisings totaling $5.2 million in April 2025. They also highlighted the elimination of a significant amount of debt through the repayment of exchangeable notes.

Decreased Operating Expenses

Total operating expenses were $3.7 million in Q1 2025, compared to $6.2 million in Q1 2024, showing a significant reduction in costs.

Reduction in R&D Expenses

R&D costs were approximately $600,000 in Q1 2025, compared to $4 million in Q1 2024, primarily due to decreased costs associated with the REASSURE trial.

Extended Cash Runway

The company has extended its cash runway into 2026, including the potential launch of ORLYNVAH by Q4 2025.

Potential Market for ORLYNVAH

The U.S. market for uncomplicated urinary tract infections is large, with 40 million prescriptions annually. ORLYNVAH could capture a market share leading to over $250 million in net sales at peak.

Repayment of Debt

In January 2025, Iterum Therapeutics repaid the outstanding principal and interest on its exchangeable notes, eliminating a significant debt liability.

Iterum Therapeutics (ITRM) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ITRM Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 05, 2025	2025 (Q2)	-0.11 / -	-0.23	―	―	―
May 13, 2025	2025 (Q1)	-0.14 / -0.10	-0.38	73.68% (+0.28)	―
Feb 07, 2025	2024 (Q4)	-0.17 / -0.12	-0.81	85.19% (+0.69)	―
Nov 14, 2024	2024 (Q3)	-0.17 / -0.24	-1.2	80.00% (+0.96)	―
Aug 14, 2024	2024 (Q2)	-0.45 / -0.23	-0.77	70.13% (+0.54)	―
May 13, 2024	2024 (Q1)	-0.72 / -0.38	-0.58	34.48% (+0.20)	―
Mar 28, 2024	2023 (Q4)	-0.94 / -0.81	-0.66	-22.73% (-0.15)	―
Nov 14, 2023	2023 (Q3)	-0.88 / -1.20	-0.43	-179.07% (-0.77)	―
Aug 11, 2023	2023 (Q2)	-0.72 / -0.77	-0.45	-71.11% (-0.32)	―	―
May 12, 2023	2023 (Q1)	-0.71 / -0.58	-0.45	-28.89% (-0.13)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ITRM Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 13, 2025	$1.01	$0.94	-6.93%
Feb 07, 2025	$1.49	$1.43	-4.03%
Nov 14, 2024	$1.43	$1.36	-4.90%
Aug 14, 2024	$1.17	$1.21	+3.42%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Iterum Therapeutics Plc (ITRM) report earnings?

Iterum Therapeutics Plc (ITRM) is schdueled to report earning on Aug 05, 2025, TBA (Confirmed).

What is Iterum Therapeutics Plc (ITRM) earnings time?

Iterum Therapeutics Plc (ITRM) earnings time is at Aug 05, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is ITRM EPS forecast?

ITRM EPS forecast for the fiscal quarter 2025 (Q2) is -0.11.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing